Drug Trial Radar · NCT05707390
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
Last checked: Nov 19, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Feb 20, 2023
Primary completion
Sep 13, 2023
Study completion Sep 13, 2023
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to measure the concentration levels of mezigdomide in the blood of participants with mild, moderate, and severe hepatic impairment, and in matched healthy control participants with normal hepatic function.
Conditions
- Hepatic Impairment
Interventions
MezigdomideDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed concentration (Cmax)Time frame: Up to 6 days
- Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-T])Time frame: Up to 6 days
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])Time frame: Up to 6 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
PANAX
Miami Lakes, Florida
Orlando Clinical Research Center OCRC
Orlando, Florida
The Texas Liver Institute
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.